|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuroki L and Guntupalli SR: Treatment of
epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Elyashiv O, Wong YNS and Ledermann JA:
Frontline maintenance treatment for ovarian cancer. Curr Oncol Rep.
23:972021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haunschild CE and Tewari KS: The current
landscape of molecular profiling in the treatment of epithelial
ovarian cancer. Gynecol Oncol. 160:333–345. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G
and Jin WL: Immunotherapy for ovarian cancer: Adjuvant,
combination, and neoadjuvant. Front Immunol. 11:5778692020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta S, Nag S, Aggarwal S, Rauthan A and
Warrier N: Maintenance therapy for recurrent epithelial ovarian
cancer: Current therapies and future perspectives-a review. J
Ovarian Res. 12:1032019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khayrani AC, Mahmud H, Oo AKK, Zahra MH,
Oze M, Du J, Alam MJ, Afify SM, Quora HAA, Shigehiro T, et al:
Targeting ovarian cancer cells overexpressing CD44 with
immunoliposomes encapsulating glycosylated taxol. Int J Mol Sci.
20:10422019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu L and Chen L: Progress in research on
Taxol and tumor immunotherapy. Cell Mol Biol Lett. 24:402019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ashrafizadeh M, Mirzaei S, Hashemi F,
Zarrabi A, Zabolian A, Saleki H, Sharifzadeh SO, Soleymani L,
Daneshi S, Hushmandi K, et al: New insight towards development of
paclitaxel and docetaxel resistance in cancer cells: EMT as a novel
molecular mechanism and therapeutic possibilities. Biomed
Pharmacother. 141:1118242021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu W, Wei T, Li Z and Zhu J: p53-dependent
apoptosis is essential for the antitumor effect of paclitaxel
response to DNA damage in papillary thyroid carcinoma. Int J Med
Sci. 18:3197–3205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao S, Tang Y, Wang R and Najafi M:
Mechanisms of cancer cell death induction by paclitaxel: An updated
review. Apoptosis. 27:647–667. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nan G, Zhao SH, Wang T, Chao D, Tian RF,
Wang WJ, Fu X, Lin P, Guo T, Wang B, et al: CD147 supports
paclitaxel resistance via interacting with RanBP1. Oncogene.
41:983–996. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Gan H, Zhao F, Ma X, Xie X, Huang
R and Zhao J: CPEB4-promoted paclitaxel resistance in ovarian
cancer in vitro relies on translational regulation of CSAG2. Front
Pharmacol. 11:6009942021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Q, Li X, Sun W, Sun M, Li Z, Sheng H,
Xie F, Zhang S and Shan C: Targeting G6PD reverses paclitaxel
resistance in ovarian cancer by suppressing GSTP1. Biochem
Pharmacol. 178:1140922020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szenajch J, Szabelska-Beręsewicz A,
Świercz A, Zyprych-Walczak J, Siatkowski I, Góralski M, Synowiec A
and Handschuh L: Transcriptome remodeling in gradual development of
inverse resistance between paclitaxel and cisplatin in ovarian
cancer cells. Int J Mol Sci. 21:92182020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang R, Wen P, Yang G, Feng Y, Mi Y, Wang
X, Zhu S and Chen YQ: N-glycosylation of GDF15 abolishes its
inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer
cells. Cell Death Dis. 13:6262022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He MX, Cuoco MS, Crowdis J, Bosma-Moody A,
Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, et al:
Transcriptional mediators of treatment resistance in lethal
prostate cancer. Nat Med. 27:426–433. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu J, Zheng M, Qi Y, Wang H, Liu M, Liu Q
and Lin B: Lewis(y) antigen-mediated positive feedback loop induces
and promotes chemotherapeutic resistance in ovarian cancer. Int J
Oncol. 53:1774–1786. 2018.PubMed/NCBI
|
|
21
|
Zhu S, Yang N, Niu C, Wang W, Wang X, Bai
J, Qiao Y, Deng S, Guan Y and Chen J: The miR-145-MMP1 axis is a
critical regulator for imiquimod-induced cancer stemness and
chemoresistance. Pharmacol Res. 179:1061962022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sansing HA, Sarkeshik A, Yates JR, Patel
V, Gutkind JS, Yamada KM and Berrier AL: Integrin αβ1, αvβ, α6β
effectors p130Cas, Src and talin regulate carcinoma invasion and
chemoresistance. Biochem Biophys Res Commun. 406:171–176. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Von Der Heyde S, Wagner S, Czerny A,
Nietert M, Ludewig F, Salinas-Riester G, Arlt D and Beißbarth T:
mRNA profiling reveals determinants of trastuzumab efficiency in
HER2-positive breast cancer. PLoS One. 10:e01178182015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong X, Liu W, Li X, Gan Y, Zhou L, Li W
and Xie L: Butein promotes ubiquitination-mediated survivin
degradation inhibits tumor growth and overcomes chemoresistance.
Sci Rep. 12:206442022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tribollet V, Cerutti C, Géloën A, Berger
E, De Mets R, Balland M, Courchet J, Vanacker JM and Forcet C: ERRα
coordinates actin and focal adhesion dynamics. Cancer Gene Ther.
29:1429–1438. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Janiszewska M, Primi MC and Izard T: Cell
adhesion in cancer: Beyond the migration of single cells. J Biol
Chem. 295:2495–2505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu QR, Du XH, Huang TT, Zheng YC, Li YL,
Huang DY, Dai HQ, Li EM and Fang WK: Role of cell-cell junctions in
oesophageal squamous cell carcinoma. Biomolecules. 12:13782022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liao YH, Chiang KH, Shieh JM, Huang CR,
Shen CJ, Huang WC and Chen BK: Epidermal growth factor-induced
ANGPTL4 enhances anoikis resistance and tumour metastasis in head
and neck squamous cell carcinoma. Oncogene. 36:2228–2242. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Legerstee K, Geverts B, Slotman JA and
Houtsmuller AB: Dynamics and distribution of paxillin, vinculin,
zyxin and VASP depend on focal adhesion location and orientation.
Sci Rep. 9:104602019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan M, Xie F, Xia X, Zhong K, Lian L,
Zhang S, Yuan L and Ye J: UNC5C-knockdown enhances the growth and
metastasis of breast cancer cells by potentiating the integrin
α6/β4 signaling pathway. Int J Oncol. 56:139–150. 2020.PubMed/NCBI
|
|
31
|
Du G, Wang J, Zhang T, Ding Q, Jia X, Zhao
X, Dong J, Yang X, Lu S, Zhang C, et al: Targeting Src family
kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro
and in vivo. Cell Death Dis. 11:1182020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ashrafizaveh S, Ashrafizadeh M, Zarrabi A,
Husmandi K, Zabolian A, Shahinozzaman M, Aref AR, Hamblin MR,
Nabavi N, Crea F, et al: Long non-coding RNAs in the doxorubicin
resistance of cancer cells. Cancer Lett. 508:104–114. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lohan-Codeço M, Barambo-Wagner ML,
Nasciutti LE, Ribeiro Pinto LF, Meireles Da Costa N and Palumbo A
Jr: Molecular mechanisms associated with chemoresistance in
esophageal cancer. Cell Mol Life Sci. 79:1162022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Rojas P, Mao J, Mustè Sadurnì M,
Garnier O, Xiao S, Higgs MR, Garcia P and Saponaro M: Persistence
of RNA transcription during DNA replication delays duplication of
transcription start sites until G2/M. Cell Rep. 34:1087592021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang YH, Mao JW and Tan XL: Research
progress on the source, production, and anti-cancer mechanisms of
paclitaxel. Chin J Nat Med. 18:890–897. 2020.PubMed/NCBI
|
|
36
|
Kitamura N, Sento S, Yoshizawa Y, Sasabe
E, Kudo Y and Yamamoto T: Current trends and future prospects of
molecular targeted therapy in head and neck squamous cell
carcinoma. Int J Mol Sci. 22:2402020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miller DS, Filiaci VL, Mannel RS, Cohn DE,
Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell
MA, et al: Carboplatin and paclitaxel for advanced endometrial
cancer: Final overall survival and adverse event analysis of a
phase III trial (NRG oncology/GOG0209). J Clin Oncol. 38:3841–3850.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Llueca A, Serra A, Climent MT, Segarra B,
Maazouzi Y, Soriano M and Escrig J; on behalf MUAPOS Working Group,
: Outcome quality standards in advanced ovarian cancer surgery.
World J Surg Oncol. 18:3092020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu
L, Li X, Tao D, Gong J and Xie D: Hippo component YAP promotes
focal adhesion and tumour aggressiveness via transcriptionally
activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer
Res. 37:1752018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu Y, Tao Z, Chen Y, Lin S, Zhu M, Ji W,
Liu X, Li T and Hu X: Exosomal MMP-1 transfers metastasis potential
in triple-negative breast cancer through PAR1-mediated EMT. Breast
Cancer Res Treat. 193:65–81. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang G, Li T, Tan G, Song Y, Liu Q, Wang
K, Ai J, Zhou Z and Li W: Identity of MMP1 and its effects on tumor
progression in head and neck squamous cell carcinoma. Cancer Med.
11:2516–2530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yan R, Ge X, Pang N, Ye H, Yuan L, Cheng
B, Zhou K, Yang M, Sun Y, Zhang S, et al: Essential role of zyxin
in platelet biogenesis and glycoprotein Ib-IX surface expression.
Cell Death Dis. 12:9552021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Partynska A, Gomulkiewicz A, Dziegiel P
and Podhorska-Okolow M: The role of zyxin in carcinogenesis.
Anticancer Res. 40:5981–5988. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cooper J and Giancotti FG: Integrin
signaling in cancer: Mechanotransduction, stemness, epithelial
plasticity, and therapeutic resistance. Cancer Cell. 35:347–367.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lu Q, Lai Y, Zhang H, Ren K, Liu W, An Y,
Yao J and Fan H: Hesperetin inhibits TGF-β1-induced migration and
invasion of triple negative breast cancer MDA-MB-231 cells via
suppressing Fyn/Paxillin/RhoA pathway. Integr Cancer Ther.
21:153473542210869002022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Katreddy RR, Bollu LR, Su F, Xian N,
Srivastava S, Thomas R, Dai Y, Wu B, Xu Y, Rea MA, et al: Targeted
reduction of the EGFR protein, but not inhibition of its kinase
activity, induces mitophagy and death of cancer cells through
activation of mTORC2 and Akt. Oncogenesis. 7:52018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao
P, Zhang L, Chen ZS and Zou C: Epitranscriptomics and epiproteomics
in cancer drug resistance: Therapeutic implications. Signal
Transduct Target Ther. 5:1932020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ashrafizadeh M, Zarrabi A, Hushmandi K,
Kalantari M, Mohammadinejad R, Javaheri T and Sethi G: Association
of the epithelial-mesenchymal transition (EMT) with cisplatin
resistance. Int J Mol Sci. 21:40022020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tulchinsky E, Demidov O, Kriajevska M,
Barlev NA and Imyanitov E: EMT: A mechanism for escape from
EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev
Cancer. 1871:29–39. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shen Q, Hill T, Cai X, Bui L, Barakat R,
Hills E, Almugaiteeb T, Babu A, Mckernan PH, Zalles M, et al:
Physical confinement during cancer cell migration triggers
therapeutic resistance and cancer stem cell-like behavior. Cancer
Lett. 506:142–151. 2021. View Article : Google Scholar : PubMed/NCBI
|
